Catalyst Biosciences Book Value 2011-2026 | CBIO

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Catalyst Biosciences

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
78.5 M	72.2 M	41.1 M	76.1 M	68.3 M	120 M	30.8 M	16.1 M	31.4 M	109 M	135 M	176 M	174 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
176 M	16.1 M	86.8 M

Quarterly Book Value Catalyst Biosciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
137 M	129 M	104 M	98.4 M	98.5 M	93.3 M	88.8 M	78.5 M	3.52 M	5 M	7.36 M	11.6 M	29.4 M	79.1 M	27.1 M	41.1 M	60.7 M	85.2 M	104 M	76.1 M	76.1 M	76.1 M	76.1 M	68.3 M	68.3 M	68.3 M	68.3 M	120 M	120 M	120 M	120 M	30.8 M	30.8 M	30.8 M	30.8 M	16.1 M	16.1 M	16.1 M	16.1 M	31.4 M	31.4 M	31.4 M	31.4 M	-475 K	-475 K	109 M	109 M	1.63 M	135 M	135 M	135 M	176 M	176 M	176 M	176 M	174 M	174 M	174 M	174 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
176 M	-475 K	79.3 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Biogen BIIB	16.7 B	$ 173.17	0.92 %	$ 25.2 B	USA
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	50.5 M	$ 2.4	-3.61 %	$ 135 M	China
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
BioNTech SE BNTX	19.4 B	$ 117.62	1.41 %	$ 27.2 B	Germany
Aptorum Group Limited APM	11.8 M	$ 0.98	1.35 %	$ 5.34 M	China
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.67	3.38 %	$ 8.83 B	Australia
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
BioXcel Therapeutics BTAI	-93.1 M	$ 1.77	-2.75 %	$ 4.49 M	USA
BioLineRx Ltd. BLRX	13.5 M	$ 3.12	0.59 %	$ 908 M	Israel
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Cellectis S.A. CLLS	131 M	$ 4.13	-6.56 %	$ 116 M	France
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-106 M	$ 233.49	-0.81 %	$ 5 B	Danmark
Burford Capital Limited BUR	1.66 B	$ 9.71	-0.46 %	$ 1.57 B	Britain
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Arrowhead Pharmaceuticals ARWR	1.39 B	$ 67.41	0.54 %	$ 9.02 B	USA
Compugen Ltd. CGEN	132 M	$ 2.04	-2.39 %	$ 183 M	Israel
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 4.36	-2.46 %	$ 9.49 B	Israel
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	518 M	-	-	$ 1.01 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Adaptimmune Therapeutics plc ADAP	39.5 M	-	-15.15 %	$ 60.3 M	Britain
Amphastar Pharmaceuticals AMPH	732 M	$ 26.57	2.51 %	$ 1.29 B	USA
Coherus BioSciences CHRS	-193 M	$ 2.26	9.7 %	$ 213 M	USA
Amneal Pharmaceuticals AMRX	3.5 B	$ 13.59	1.46 %	$ 4.2 B	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Celldex Therapeutics CLDX	747 M	$ 26.72	3.09 %	$ 1.72 M	USA
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	124 M	$ 2.75	1.85 %	$ 17.3 M	USA
AstraZeneca PLC AZN	40.9 B	$ 94.24	1.38 %	$ 96.9 B	Britain
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA